Germany’s antibiotic crisis deepens as benzathine benzylpenicillin runs dangerously low

Germany is facing a critical shortage of benzathine benzylpenicillin, a vital injectable antibiotic. The Federal Ministry of Health has officially declared the shortage, which also affects other key antibiotics like cefuroxime, clindamycin, and erythromycin. Experts had warned about the problem as early as September 2022.

Benzathine benzylpenicillin is essential for treating chronic streptococcal infections and preventing rheumatic fever. It works by breaking down bacterial cell walls, making it a key drug in the beta-lactam class. The shortage stems from dwindling supplies at Infectopharm Arzneimittel u. Consilium GmbH, the German manufacturer of Tardocillin and Pendysin.

Current stocks are expected to run out by early 2026. To address the gap, authorities plan to ease regulatory rules temporarily, allowing faster approval of imported alternatives. The crisis extends beyond benzathine benzylpenicillin. Other antibiotics, including cefuroxime, clindamycin, cotrimoxazole, and erythromycin, are also in short supply. The government is working to secure alternative sources while maintaining treatment standards.

The shortage will persist until early 2026 unless imports fill the gap. Regulatory changes aim to speed up the approval of foreign-supplied antibiotics. Patients relying on these drugs may face delays, but officials are taking steps to prevent treatment disruptions.